|
Recent Developments |
|
13-NOV-13
ICRA has upgraded the long term rating for Rs 9.48 billion of bank facilities of Ind Swift Laboratories to C from D. ICRA has also upgraded short term rating for Rs 2.99 billion of bank facilities of the company to A4 from D. The total rated limits are Rs 12.13 billion.
16-MAY-12
Ind-Swift added another feather in its cap by launching generic formulations of the World`s best selling drug Atorvastatin in UK in collaboration with Wock... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2021 (12) | 31-Mar-2020 (12) | 31-Mar-2019 (12) | | Net sales | 8565.78 | 7518.37 | 7244.28 | | Other Income | 231.28 | 360.20 | 374.64 | | Total Income | 8797.06 | 7878.57 | 7618.92 | | Cost of goods sold | -8635.89 | -8074.18 | -7764.05 | | OPBDIT | 17432.95 | 15952.75 | 15382.97 | | PAT | -43.98 | -207.87 | 480.74 | | Gross Block | - | - | - | | Equity capital | 0.00 | 0.00 | 0.00 | | EPS (Rs.) | 0.00 | 0.00 | 0.00 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | NA | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 198.2 | 202.5 | 201.9 | | Net margin (% of OI) | -0.5 | -2.6 | 6.3 |
|
|
Detailed Financials
|
|
|
|
|
